MARKET

EGRX

EGRX

Eagle Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.32
-0.08
-0.20%
After Hours: 40.32 0 0.00% 16:41 03/03 EST
OPEN
40.54
PREV CLOSE
40.40
HIGH
42.17
LOW
39.90
VOLUME
133.79K
TURNOVER
--
52 WEEK HIGH
56.16
52 WEEK LOW
33.80
MARKET CAP
525.37M
P/E (TTM)
113.77
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Trading At A 21% Discount?
Today we will run through one way of estimating the intrinsic value of Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ) by...
Simply Wall St. · 16h ago
DJ Eagle Pharmaceuticals, Inc. CEO Scott Tarriff on Q4 2020 Results -- Earnings Call Transcript >EGRX
Dow Jones · 1d ago
8-K: EAGLE PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- 0000827871 false 0000827871 2021-03-02 2021-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings Estimates
Zacks.com · 1d ago
BRIEF-Eagle Pharmaceuticals Reports Q4 Adjusted Non-GAAP Earnings Per Share $0.96
reuters.com · 1d ago
Eagle Pharmaceuticals EPS beats by $1.16, misses on revenue
Eagle Pharmaceuticals (EGRX): Q4 Non-GAAP EPS of $0.96 beats by $1.16; GAAP EPS of $0.60 beats by $2.02.Revenue of $49.9M (+3.4% Y/Y) misses by $1.96M.Press Release
Seekingalpha · 1d ago
Eagle Pharmaceuticals Sees 2021 Adjusted R&D Spend $26M-$30M >EGRX
Eagle Pharmaceuticals Sees 2021 Adjusted R&D Spend $26M-$30M >EGRX
Dow Jones · 1d ago
Eagle Pharmaceuticals 4Q Rev $49.9M >EGRX
Eagle Pharmaceuticals 4Q Rev $49.9M >EGRX
Dow Jones · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EGRX. Analyze the recent business situations of Eagle Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EGRX stock price target is 49.67 with a high estimate of 57.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 278
Institutional Holdings: 15.70M
% Owned: 120.48%
Shares Outstanding: 13.03M
TypeInstitutionsShares
Increased
48
753.04K
New
41
-242.79K
Decreased
70
982.89K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.99%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
Michael Graves
President/Chief Operating Officer
David Pernock
Chief Executive Officer/Director
Scott Tarriff
Chief Financial Officer/Chief Accounting Officer
Brian Cahill
Independent Director
Richard Edlin
Independent Director
Robert Glenning
Independent Director
Steven Ratoff
Independent Director
Jennifer Simpson
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About EGRX
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Webull offers kinds of Eagle Pharmaceuticals Inc stock information, including NASDAQ:EGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EGRX stock methods without spending real money on the virtual paper trading platform.